Management of Laryngeal Squamous Cell Carcinoma
All patients with laryngeal cancer should be managed through a multidisciplinary team at high-volume facilities, with treatment decisions prioritizing both survival and functional outcomes including voice preservation 1.
Early-Stage Disease (T1-T2)
Early laryngeal cancer should be treated with single-modality therapy—either surgery or radiotherapy alone—as both provide equivalent locoregional control 1, 2. The choice between these modalities depends on:
- Tumor location and extent: Glottic T1 tumors have <10% risk of nodal metastasis and can be observed without elective neck treatment 3
- Expected functional outcomes: Voice quality, swallowing function
- Patient comorbidities and preferences
Radiation Technique
- Use IMRT or VMAT exclusively (not conventional 2D techniques) 1
- Deliver at least 1000 cGy per week to prevent accelerated tumor repopulation 4
- For early glottic cancer, avoid fraction sizes <200 cGy as this increases recurrence 4
Locally Advanced Disease (T3-T4)
For T3/T4 laryngeal cancer, two standard approaches exist: primary surgical resection followed by adjuvant (chemo)radiotherapy, OR definitive concurrent chemoradiotherapy 1.
When to Choose Surgery First
Primary surgical treatment followed by RT or CRT is preferred specifically for T4 laryngeal cancers 1. This means:
- Tumor invasion through cartilage into soft tissues
- Extensive thyroid cartilage destruction
- Extralaryngeal spread
When to Choose Definitive Chemoradiotherapy
For most T3 and T4 tumors WITHOUT cartilage invasion through to soft tissues, concurrent chemoradiotherapy is the most widely applicable larynx-preservation approach 1, 2.
Standard concurrent chemoradiotherapy regimen: Cisplatin 100 mg/m² on days 1,22, and 43 with concurrent radiotherapy to 70 Gy 1.
Alternatives for Cisplatin-Ineligible Patients
For patients unfit for high-dose cisplatin 1:
- Carboplatin + 5-FU concurrent with RT
- Cetuximab concurrent with RT
- Hyperfractionated or accelerated RT without chemotherapy
Larynx Preservation Strategy
For larynx preservation specifically, induction chemotherapy with TPF (docetaxel/cisplatin/5-FU) for three cycles followed by radiotherapy alone is a validated option 1. However:
- Induction chemotherapy is NOT routinely recommended outside the larynx preservation context
- It does not improve overall survival compared to concurrent chemoradiotherapy
- Reserve for patients where larynx preservation is the primary goal and you need tumor response assessment before committing to radiotherapy
Neck Management
Clinically Node-Negative (cN0)
Supraglottic tumors: Highest risk of occult nodal disease (20-50%, >50% in T3-T4). Perform elective bilateral selective neck dissection of levels II-IV 3.
Advanced glottic tumors (T3-T4): 15-30% occult metastasis risk—elective neck treatment indicated 3.
Early glottic tumors (T1-T2): <10% nodal risk—observation acceptable 3.
Subglottic tumors: Include level VI in neck dissection due to paratracheal drainage 3.
Clinically Node-Positive (cN+)
- N1-N2 disease: Selective neck dissection
- N3 disease: Modified radical neck dissection 1
Post-Chemoradiotherapy Assessment
Do NOT perform neck dissection if FDG-PET is negative AND lymph nodes are normal size at 12 weeks post-CRT 1. This avoids unnecessary surgery in complete responders.
Postoperative Adjuvant Therapy
Indications for Postoperative Radiotherapy Alone
Recommend postoperative RT (60-66 Gy) for 1:
- pT3-T4 tumors
- Perineural infiltration
- Lymphovascular invasion
1 positive lymph node (without extracapsular extension)
Indications for Postoperative Chemoradiotherapy
Postoperative concurrent chemoradiotherapy is mandatory for 1:
- Positive margins (R1 resection)
- Extracapsular extension
Use the same cisplatin regimen (100 mg/m² days 1,22,43) with RT to 66 Gy.
Critical timing: Start postoperative RT or CRT within 6-7 weeks of surgery 1. Delays beyond this significantly compromise outcomes.
Recurrent/Metastatic Disease
First-Line Systemic Therapy
For PD-L1 positive tumors (CPS ≥1): Two FDA/EMA-approved options 1:
- Pembrolizumab + platinum/5-FU: Use when rapid tumor shrinkage needed
- Pembrolizumab monotherapy: Appropriate for slower-growing disease
For PD-L1 negative tumors: Platinum/5-FU/cetuximab (EXTREME regimen) remains standard 1.
Test DPD levels before initiating 5-FU to avoid severe toxicity in deficient patients 1.
Second-Line After Platinum Failure
Nivolumab is FDA and EMA-approved for patients progressing within 6 months of platinum therapy (median OS 7.5 vs 5.1 months with single-agent chemotherapy) 1.
Pembrolizumab is FDA-approved for the same indication, and EMA-approved specifically for PD-L1 TPS ≥50% (median OS 11.6 vs 6.6 months in this subset) 1.
Third-Line and Beyond
After progression on both platinum and anti-PD-1 therapy, no standard of care exists 1. Options include:
- Cetuximab (FDA-approved, median OS 5.2-6.1 months based on single-arm studies) 1
- Taxanes ± cetuximab/methotrexate (no randomized trial support) 1
Critical Pitfalls to Avoid
Do not use conventional 2D radiotherapy—IMRT/VMAT is mandatory to reduce toxicity while maintaining efficacy 1
Do not delay postoperative radiotherapy beyond 6-7 weeks—this significantly worsens outcomes 1
Do not perform neck dissection at 12 weeks post-CRT if PET-negative—you'll only add morbidity without benefit 1
Do not use induction chemotherapy routinely—it's validated only for larynx preservation, not for improving survival 1
Do not treat HPV-positive and HPV-negative laryngeal cancer differently—unlike oropharyngeal cancer, treatment de-escalation is not validated 1
Do not forget to test DPD before 5-FU—deficiency causes life-threatening toxicity 1